Selected References:
- Aljazaf K, et al. 2003. Pseudoephedrine: effects on milk production in women and estimation of infant exposure via breastmilk. Br J Clin Pharmacol 56(1):18- 24.
- Anastasio GD, et al. 1992. Fetal tachycardia associated with maternal use of pseudoephedrine, an over-the-counter oral decongestant. J Am Board Fam Pract 5(5):527-8.
- Eglash A. 2014. Treatment of maternal hypergalactia. Breastfeed Med. 9:423-5.
- Findlay JW, et al. 1984. Pseudoephedrine and triprolidine in plasma and breast milk of nursing mothers. Br J Clin Pharmacol 18(6):901-906.
- Głowacka K, et al. 2021. Pseudoephedrine-Benefits and Risks. Int J Mol Sci; 22(10):5146. PMID: 34067981 PMCID: PMC8152226 DOI: 10.3390/ijms22105146
- Heinonen OP, et al. 1977. Birth Defects and Drugs in Pregnancy. Littleton, MA: John Wright-PSG. pp 345-56.
- Ito S, et al. 1993. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol 168(5):1393-1399.
- Miller RK. 1992. From the pages of Teratology: vitamin A to pseudoephedrine issues in patient counseling. Teratology 45(4):341-343.
- Rosa F. 1993. Personal communication. Cited in: Briggs GG, et al. 2005. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Seventh Edition. Baltimore, MD: Williams & Wilkins.
- Schatz M, et al. 1997. Asthma and allergy in pregnancy. Clin Perinatol 24(2):407-432.
- Smith J, et al. 1994. Drugs of choice for pregnant women. In: Koren G. Maternal-fetal Toxicology. A Clinician’s Guide. 1994. Second Edition. New York NY: Marcel Dekker Inc.
- Soussan C, et al. 2014. Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database. Eur J Clin Pharmacol.70:1361-6.
- Torfs CP, et al. 1996. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 54(2):84-92.
- Yau W-P, et al. 2013. Use of decongestants during pregnancy and the risk of birth defects. Am J Epidemiol. 178(2):198-208.
- Werler MM, et al. 2003. Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. Epidemiology 14(3):349-54.
- Werler MM, et al. 1992. First trimester maternal medication use in relation to gastroschisis. Teratology 45(4):361-367.
- Werler MM, et al. 2002. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 155(1):26-31.
- Werler MM, et al. 2004. Vasoactive exposures, vascular events, and hemifacial microsomia. Birth Defects Res A Clin Mol Teratol 70(6):389-395.
